Janssen(强生)COVID-19疫苗安全性监测——美国,2021年3-4月
本文总结了2021年3-4月美国Janssen COVID-19疫苗(单剂腺病毒载体)接种后不良事件监测结果。v-safe主动监测中约338,700名接种者完成至少一次调查,76%报告全身反应。监测发现3例非CVST的血栓形成伴血小板减少综合征(TTS)病例,加上此前导致暂停使用的CVST病例,共识别17例TTS,整体安全性特征与授权前临床试验数据一致。
要点
- v-safe主动监测中约338,700名接种者完成至少一次调查,76%报告全身反应,61%报告局部反应,34%报告健康影响。
- 监测发现3例非CVST的TTS病例,与既往CVST病例合计17例TTS,需持续监测以评估风险获益。
核心结论
- Janssen COVID-19疫苗整体安全性特征与授权前临床试验数据一致,但监测发现包括非CVST的TTS在内的血栓伴血小板减少事件,需持续监测以评估各疫苗风险获益。
研究设计与样本
- 基于美国VAERS被动监测系统和v-safe主动监测系统,对2021年3-4月Janssen COVID-19疫苗接种后不良事件进行总结分析。
- 截至2021年4月21日,共接种7.98百万剂Janssen COVID-19疫苗;VAERS共审查13,725份报告;约338,700名接种者完成至少一次v-safe调查。
主要发现
- VAERS审查的13,725份报告中,97%归类为非严重事件,3%归类为严重事件。
- VAERS报告中发现3例女性在接种后第二周出现大动脉或大静脉血栓伴血小板减少的非CVST病例。
- 上述3例与先前检测到的CVST病例共同符合17例新定义的血栓形成伴血小板减少综合征(TTS)。
- v-safe调查中约338,700名接种者完成至少一次调查,76%报告全身反应,61%报告局部反应,34%报告健康影响。
- VAERS和v-safe中疲劳和疼痛均为常见报告症状。
关键数值与推荐
- 2021年2月27日FDA对Janssen COVID-19疫苗(Ad.26.COV2.S)颁发紧急使用授权(EUA)。
- 2021年2月28日ACIP发布Janssen COVID-19疫苗在≥18岁人群中使用的临时推荐。
- 2021年4月13-23日,CDC和FDA在报告6例CVST伴血小板减少(血小板计数<150,000/μL)后建议暂停使用Janssen疫苗。
临床怎么用
- 接种Janssen COVID-19疫苗后应关注血栓伴血小板减少症状,尤其是接种后第二周出现的非CVST的TTS病例。
- 持续通过VAERS和v-safe等系统监测COVID-19疫苗接种后不良事件,以评估各疫苗的风险与获益。
局限性
- VAERS为被动监测系统,可能存在报告偏倚和漏报。
- v-safe为主动监测系统,但调查完成率及代表性可能受限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
On February 27, 2021, the Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for Janssen (Ad.26.COV2.S) COVID-19 vaccine (Janssen Biotech, Inc., a Janssen Pharmaceutical company, Johnson & Johnson) (1). The Janssen COVID-19 vaccine, the third COVID-19 vaccine authorized for use in the United States, uses a replication-incompetent human adenoviral type 26 vector platform* (2) and is administered as a single intramuscular dose, whereas the first two authorized vaccines use an mRNA platform and require 2 doses. On February 28, 2021, the Advisory Committee on Immunization Practices (ACIP) issued interim recommendations for use of Janssen COVID-19 vaccine among persons aged ≥18 years (3). During April 13-23, CDC and FDA recommended a pause in use of Janssen vaccine after reports of six cases of cerebral venous sinus thrombosis (CVST) with thrombocytopenia (platelet count <150,000/μL of blood) among Janssen vaccine recipients (4). Similar thrombotic events, primarily among women aged <60 years, have been described in Europe after receipt of the AstraZeneca COVID-19 vaccine, which uses a replication-incompetent chimpanzee adenoviral vector (5-7). The U.S. CVST cases that prompted the pause in Janssen vaccination, as well as subsequently detected CVST cases, are described elsewhere (8). This report summarizes adverse events among Janssen vaccine recipients, including non-CVST cases of thrombosis with thrombocytopenia syndrome (TTS), reported to the Vaccine Adverse Events Reporting System (VAERS), a passive surveillance system, and through v-safe, an active monitoring system. As of April 21, 2021, 7.98 million doses of the Janssen COVID-19 vaccine had been administered. Among 13,725 VAERS reports reviewed, 97% were classified as nonserious and 3% as serious,† including three reports among women of cases of thrombosis in large arteries or veins accompanied by thrombocytopenia during the second week after vaccination. These three cases and the previously detected CVST cases are consistent with 17 cases of TTS,§ a newly defined condition. Approximately 338,700 Janssen COVID-19 vaccine recipients completed at least one v-safe survey during the week after vaccination; 76% reported a systemic reaction, 61% reported a local reaction, and 34% reported a health impact.¶ Fatigue and pain were commonly reported symptoms in both VAERS and v-safe. The overall safety profile is consistent with preauthorization clinical trials data. Prompt review of U.S. vaccine safety data detected three additional cases of non-CVST TTS, in addition to the previously recognized CVST cases that initiated the pause in use of the Janssen COVID-19 vaccine. Ongoing monitoring of adverse events after COVID-19 vaccination, including vaccination with the Janssen single-dose vaccine, is essential for evaluating the risks and benefits of each vaccine.
引用
- Shay DK, Gee J, Su JR, et al. Safety Monitoring of the Janssen (Johnson & Johnson) COVID-19 Vaccine - United States, March-April 2021. MMWR Morb Mortal Wkly Rep. 2021. PMID: 33956784. doi:10.15585/mmwr.mm7018e2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。